TRACON Pharmaceuticals Appoints Biotech Industry Veteran Mark Wiggins as Chief Business Officer
“We are excited to have a seasoned industry veteran join our team,” said Dr. Theuer. “Mark’s business development and commercialization experience, as well as his strategic vision, will be invaluable as we continue to advance our clinical programs and leverage our product development platform. During his career, Mark has launched and led sales and marketing for a multi-billion dollar oncology drug, Rituxan®, secured multiple global licensing deals and provided senior leadership at both large and small companies.”
Previously, Mr. Wiggins served as Senior Vice President of Corporate and Business Development at Elcelyx Therapeutics, and Chief Business Officer at
“I am thrilled to be joining TRACON at such an exciting time in the Company’s development,” said Mr. Wiggins. “With multiple clinical data-related catalysts upcoming, as well as a unique product development platform, TRACON is well-positioned for long-term success. I look forward to leveraging my extensive business development and commercial experience to support the Company’s strategic plan.”
About TRACON
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with
Forward-Looking Statements
Statements made in this press release regarding matters that are not historical facts are “forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward‐looking statements. Such statements include, but are not limited to, statements regarding TRACON's plans to further develop its product candidates, future contributions of Mr. Wiggins to TRACON and TRACON’s potential long-term success. Risks that could cause actual results to differ from those expressed in these forward‐looking statements include: risks associated with clinical development; whether TRACON or others will be able to complete or initiate clinical trials on TRACON’s expected timelines, if at all; the fact that future preclinical studies and clinical trials may not be successful or otherwise consistent with results from prior studies; potential changes in regulatory requirements in
Company Contact: | Investor Contact: |
Patricia Bitar | Andrew McDonald |
Chief Financial Officer | LifeSci Advisors LLC |
(858) 550-0780 ext. 223 | 646-597-6987 |
pbitar@traconpharma.com | Andrew@lifesciadvisors.com |
Source: TRACON Pharmaceuticals, Inc.